From Patient Access to Reliable Execution: What Oncology Sponsors Need from a Site

Start with an evidence-based patient-access hypothesis

A strong feasibility response explains where potential participants may come from and why they are likely to reach this site at the relevant disease point. Inputs may include historical referrals, de-identified diagnosis counts, molecular-testing pathways, treating-physician relationships, geography, payer considerations, language, and competing trials.

The estimate should be narrowed through the protocol. How many patients have the required stage, biomarker, prior therapy, performance status, organ function, and timing? How often are records complete enough for rapid review? What proportion may be lost because the next treatment cannot wait?

Sponsors should welcome a calibrated forecast. An honest “no” or a conditional commitment may protect the program more than an unsupported projection.

Examine the conversion pathway

Enrollment is the result of multiple conversions:

• •Awareness to inquiry
• •Inquiry to records received
• •Records received to preliminary protocol relevance
• •Preliminary relevance to consent
• •Consent to screen success
• •Eligibility to enrollment
• •Enrollment to evaluable treatment and follow-up

Each transition needs an owner, a timeline, a respectful patient communication process, and a method for learning why people do not continue. Screen-failure data should be clinically interpreted, not simply counted. A recurring missing biomarker, prohibited prior therapy, or travel burden may require a different intervention.

Distinguish activated from ready

Regulatory activation is a milestone; operational readiness is a condition. Before first patient in, the site should be able to demonstrate:

• •Current approved documents and role-specific training
• •Functional delegation and investigator coverage
• •Orders, worksheets, source tools, and eligibility evidence paths
• •Investigational product receipt and preparation readiness
• •Laboratory supplies, processing practice, and courier plan
• •Electronic system access and tested data workflows
• •Safety escalation and after-hours coverage
• •A rehearsed first-cycle schedule

Small unresolved items can accumulate into a delayed or fragile first enrollment. A readiness review should surface them before a candidate is waiting.

Protect direct investigator engagement

Oncology protocols frequently require judgment that cannot be reduced to a checklist: interpreting disease progression, assessing toxicity resolution, weighing medical history, evaluating performance status, or responding to a new symptom. The investigator must be available for these decisions and able to communicate directly with medical monitors when needed.

Qualification should assess actual access, not only the investigator's résumé. Ask how eligibility is approved, how safety information is reviewed, how subinvestigators are integrated, and how competing workload is managed.

Design for retention and participant experience

Retention is not persuasion. It is the result of informed expectations, manageable logistics, responsive clinical communication, and respect for voluntary choice. Sites can reduce avoidable burden by explaining visit intensity early, checking language needs, planning transportation, coordinating with caregivers, and identifying which routine services can be safely performed locally when the protocol permits.

When a participant wants to stop treatment, the team should distinguish treatment discontinuation from withdrawal of all follow-up. The conversation must respect the participant's decision while explaining safety and data follow-up options allowed by the protocol and consent.

Make data reliability visible

Sponsors need timely data, but speed without traceability creates risk. The site's source should support what happened, when, why, and who made the decision. Data processes should include contemporaneous documentation, targeted review of critical fields, query ownership, aging thresholds, and reconciliation across clinical, pharmacy, laboratory, and safety records.

Leading indicators are useful: unresolved eligibility evidence, late safety reviews, sample deviations, query aging, repeated corrections, visit-window pressure, and staff workload. The response to these signals is as important as the metric itself.

Build a two-way operating relationship

Site performance also depends on the sponsor and CRO. Timely responses to eligibility questions, clear safety communications, stable vendors, usable manuals, predictable drug supply, and proportionate monitoring enable execution. Sites should escalate clearly and early; sponsor teams should close the loop.

High-performing partnerships create a shared view of critical risks, decisions, and priorities rather than relying on a series of disconnected emails.

Our FCTG approach

At FCTG, we connect community and physician referral pathways with our research-only operating model. Our physician investigators and cross-functional leaders review every protocol opportunity across clinical fit, patient access, investigator capacity, pharmacy, laboratory, data, regulatory, and visit complexity. Our goal is to make a defensible commitment and then execute transparently—not to offer a volume promise detached from protocol reality.